/explore
|
You are here 
|
www.healthcare-economist.com | ||
| | | | |
www.drugchannels.net
|
|
| | | | | [AI summary] The article analyzes five key implications of post-election pharmacy benefit designs on patient drug affordability, out-of-pocket costs, and adherence, highlighting the complexity of commercial and Medicare Part D plans. | |
| | | | |
www.medicare.gov
|
|
| | | | | Part D (Medicare drug coverage) helps cover cost of prescription drugs, may lower your costs and protect against higher costs. | |
| | | | |
aspe.hhs.gov
|
|
| | | | | Insulin prices have increased dramatically over the past decade in the United States. This report presents results from international price comparisons of insulins using a price index approach. The average gross manufacturer price for a standard unit of insulin in 2018 was more than ten times the price in a sample of 32 foreign countries:$98.70 in the U.S., compared with $8.81 in the 32 non-U.S. OECD countries for which we have prescription drug data. The U.S. prices for the mix of insulin used in the U.... | |
| | | | |
dissidentvoice.org
|
|
| | | As an intended outcome of neoliberal doctrine and a natural stage of capitalist development, global financialization constructs a borderless nexus of power in which debt and austerity fuels a cultural, political and economic landscape bound to enduring structures of domination, and creates unprecedented wealth through the accumulation of suffering. ***** According to economist Richard Wolff, | ||
